New York, Nov. 5 – UBS AG, London Branch priced $99,994.86 of 21.17% annualized trigger yield optimization notes due Aug. 10, 2020 linked to the American depositary receipts of Teva Pharmaceutical Industries Ltd., according to a 424B2 filing with the Securities and Exchange Commission.
The face amount of each note is $8.54, which is equal to the initial share price of Teva Pharmaceutical stock.
Interest is payable monthly.
The payout at maturity will be par unless the final price of Teva Pharmaceutical stock is less than 69% of the initial share price, in which case investors will receive one Teva Pharmaceutical share per note.
UBS Financial Services Inc. and UBS Investment Bank are the underwriters.
| Issuer: | UBS AG, London Branch
|
| Issue: | Trigger yield optimization notes
|
| Underlying stock: | Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
|
| Amount: | $99,994.86
|
| Maturity: | Aug. 10, 2020
|
| Coupon: | 21.17%, payable monthly
|
| Price: | Par of $8.54
|
| Payout at maturity: | If final share price is less than trigger price, one Teva Pharmaceutical share; otherwise, par
|
| Initial share price: | $8.54
|
| Trigger price: | $5.89, 69% of initial price
|
| Pricing date: | Nov. 5
|
| Settlement date: | Nov. 7
|
| Underwriters: | UBS Financial Services Inc. and UBS Investment Bank
|
| Fees: | 1.5%
|
| Cusip: | 90288J821
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
